Humacyte, Inc. (HUMA) closed the most recent trading day at $0.78, moving -2.32% from the previous trading session. This change lagged the S&P 500's 0.79% gain on the day. Meanwhile, the Dow ...

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Humacyte’s fair value estimate has been reset from US$7.86 to US$2.05, marking a sharp recalibration of how analysts are ...

In the latest trading session, Humacyte, Inc. (HUMA) closed at $5.17, marking a -1.34% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow saw an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The latest price target for Humacyte (NASDAQ:HUMA) was reported by TD Cowen on June 17, 2026. The analyst firm set a price target for $1.25 expecting HUMA to rise to within 12 months (a possible 99.65 ...

Humacyte, Inc. (HUMA) ended the recent trading session at $1.03, demonstrating a -3.74% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of ...

On June 10, 2026, Humacyte reported positive top-line interim results from its Phase 3 V012 trial evaluating its acellular tissue engineered vessel (ATEV) for dialysis access in female patients with ...

(RTTNews) - Humacyte, Inc. (HUMA) has launched Symvess, a bioengineered vascular conduit for adults needing urgent revascularization due to extremity arterial injury when autologous vein grafts aren't ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has ...